Research > ETFs > ETF / ETP Commentary > 

The Future of Uranium Enrichment is Being Developed Today

  • Related Symbols
  • SLX
One critical step of the nuclear fuel chain, uranium enrichment, has long been a domestic vulnerability for the United States. Traditional gas-centrifuge technology has been the proven workhorse for decades, delivering low-enriched uranium (LEU) for today’s reactor fleet. Now, next-generation laser-based methods promise dramatically higher efficiency, lower energy use, smaller footprints, and faster deployment.The VettaFi Nuclear Renaissance Index (NUKZX) includes companies adding new uranium enrichment capacity and developing laser-based technologies. Importantly, these companies may not be found in other nuclear power strategies. The fuel segment of NUKZX tends to focus on uranium enrichment and conversion, with less exposure to uranium mining.   Centrus Energy (LEU) utilizes centrifuge technology while three laser players, Silex Systems (SLX), ASP Isotopes (ASPI), and LIS Technologies (private), are closing the gap toward commercial reality. Recent milestones across all four companies signal accelerating progress and open tangible investment opportunities across the nuclear value chain. Read More: Uranium Conversion Capacity Set for Major ExpansionCentrus Energy: The Established Centrifuge Leader Scales upCentrus Energy operates its uranium enrichment facility at the American Centrifuge Plant in Piketon, Ohio. Using its proprietary AC-100M advanced gas centrifuges, the company has been producing high-assay LEU (HALEU) under a Department of Energy (DOE) contract since 2023, and recently reached the milestone of 900 kilograms delivered to the DOE. Centrifuge technology remains the current standard. While proven at industrial scale, the process is capital-intensive, with large physical footprints and higher energy requirements per unit of enrichment effort. It provides a reliable baseline against which the laser approaches are measured. Centrus recently launched a centrifuge manufacturing project to support commercial-scale expansion. In January 2026, the DOE awarded Centrus a $900 million task order to build out both additional HALEU capacity (targeting 12 metric tonnes per year) and large-scale LEU production. In February 2026, Centrus partnered with Fluor (FLR) as its engineering, procurement, and construction contractor for the multi-billion-dollar Piketon expansion.Silex and GLE Scale Laser Enrichment at HomeSilex Systems is the majority owner (51%) of U.S.-based Global Laser Enrichment (GLE), with Cameco (CCJ) holding the remaining 49%. GLE is commercializing its proprietary SILEX laser enrichment technology. It operates a Test Loop pilot facility in Wilmington, North Carolina, where it completed a large-scale enrichment demonstration. GLE achieved Technology Readiness Level 6, meaning the process was tested under relevant operational conditions and is now ready for commercialization. It is continuing to produce significant quantities of LEU today. Compared with centrifuge cascades, SILEX offers higher separation factors. This is to say the enrichment process can be done in a significantly shorter time and thus more efficiently. The facilities for performing the process can also be deployed more quickly, with less capital, and on a smaller footprint than gas centrifuge plants.  GLE is advancing the Paducah Laser Enrichment Facility in Kentucky. The company will utilize old enrichment process byproducts that have been kept on site since the Manhattan Project to produce new nuclear fuel. GLE was awarded $28.5 million in DOE funding for further laser development at the beginning of the year. Last month, Kentucky approved a performance-based incentives package worth up to $98.9 million.  The NRC accepted GLE’s full license application in August 2025 and issued a draft Environmental Impact Statement in March 2026. First production remains targeted for ~2030, which would mark the world’s first commercial laser enrichment plant.ASP Isotopes and QLE target HALEU and global marketsASPI is applying its Quantum Enrichment laser technology, originally developed for medical and semiconductor isotopes, to nuclear fuel through its wholly-owned subsidiary Quantum Leap Energy (QLE). QLE is advancing commercialization in South Africa, where it operates isotope facilities in Pretoria. Quantum Leap Energy and Necsa recently advanced a strategic collaboration for HALEU production, with site work and engineering studies underway. QLE has multiple ventures underway for their laser enrichment technology. The company is working with TerraPower to finance and construct the facility in South Africa, which will be utilized to produce the first fuel for TerraPower’s reactor in Wyoming. QLE is also working with the University of Bristol in the UK to design a lithium laser enrichment research facility for potential use in fusion reactors  Like SILEX, QLE’s laser approach promises lower energy use and smaller facilities than traditional centrifuges, positioning it to complement or compete with Centrus’ HALEU ramp for advanced reactors.LIS Technologies Partners With Nano NuclearLIS Technologies (LIST) is developing the only patented, U.S.-origin laser enrichment technology,  based on Condensation Repression Isotope Selective Laser Activation (CRISLA) technology initially developed years ago. Optimized for both LEU and HALEU, it uses shorter-wavelength infrared lasers for potential efficiency gains. LIST received a Radioactive Material License from Tennessee last year for UF6 handling and testing at its Demo Test Loop in Oak Ridge. LIST has partnered with Nano Nuclear (NNE) to integrate its enriched UF6 into Nano’s fuel-manufacturing pipeline. In January, LIST announced a $1.38 billion investment in its flagship LEU-3 Facility on LIST Island at Oak Ridge. The project targets commercial operations before 2030, with site preparation and non-nuclear construction slated for later this year. LIST’s laser platform, like its peers, targets the same efficiency and compactness advantages over the centrifuge baseline Centrus is expanding today.Bottom Line:Multiple companies are addressing the lack of domestic enrichment capacity in the U.S.. Centrus is attacking the problem using tried and tested gas centrifuge technology, while next generation technology developers like Silex, ASPI, and LIST are advancing their laser designs with significant potential gains in efficiency and reduced costs. For investors, the developments translate into exposure across the nuclear value chain. LEU, SLX, and ASPI are constituents of the VettaFi Nuclear Renaissance Index (NUKZX) in the fuel category, while NNE (LIST’s key partner) sits in the advanced-reactors category. NUKZX includes companies across the nuclear value chain, from fuel to utilities. NUKZX is the underlying index for the Range Nuclear Renaissance Index ETF (NUKZ ). For more news, information, and analysis, visit VettaFi | ETFDB.

Performance data shown is past performance and is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore you have a gain or loss when you sell your shares. For standard quarterly performance, go to the fund's Snapshot page by clicking on the ETF/ETP's symbol.

ETFs may trade at a premium or discount to their NAV and are subject to the market fluctuations of their underlying investments.

For iShares ETFs, Fidelity receives compensation from the ETF sponsor and/or its affiliates in connection with an exclusive long-term marketing program that includes promotion of iShares ETFs and inclusion of iShares funds in certain FBS platforms and investment programs. Please note, this security will not be marginable for 30 days from the settlement date, at which time it will automatically become eligible for margin collateral. Additional information about the sources, amounts, and terms of compensation can be found in the ETF's prospectus and related documents. Fidelity may add or waive commissions on ETFs without prior notice. BlackRock and iShares are registered trademarks of BlackRock, Inc. and its affiliates.

FBS receives compensation from the fund's advisor or its affiliates in connection with a marketing program that includes the promotion of this security and other ETFs to customers ("Marketing Program"). The Marketing Program creates incentives for FBS to encourage the purchase of certain ETFs. Additional information about the sources, amounts, and terms of compensation is in the ETF's prospectus and related documents. Please note that this security will not be marginable for 30 days from the settlement date, at which time it will automatically become eligible for margin collateral.

News, commentary (including "Related Symbols") and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended to help self-directed investors evaluate exchange traded products (ETPs), including, but limited to exchange traded funds (ETFs) and exchange traded notes (ETNs). Criteria and inputs entered, including the choice to make ETP comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a particular security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating ETPs. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use. Determine which securities are right for you based on your investment objectives, risk tolerance, financial situation and other individual factors and re-evaluate them on a periodic basis.

Before investing in any exchange traded product, you should consider its investment objective, risks, charges and expenses. Contact Fidelity for a prospectus, offering circular or, if available, a summary prospectus containing this information. Read it carefully.